Laszlo Urban Global Head, Preclinical Safety Profiling Novartis Laszlo is Global Head of Preclinical Safety Profiling at Novartis. Since 2001, he has been leading a pharmaceutical research department developing methods and strategy for preclinical safety assessment. Read more...
Federico Goodsaid VP, Strategic Regulatory Intelligence Vertex Pharmaceuticals Federico’s work at Vertex is focused on early and effective interaction and collaborations on exploratory biomarkers with regulatory agencies having previously worked as Biomarker Qualification Coordinator for the FDA.
Eric Chiao Head, Pluripotent Stem Cell Lab, Non-Clincal Safety Roche Eric was founding Director of the Human Pluripotent Stem Cell facility at Stanford before joining Hoffmann-La Roche in 2010 as the head of the Pluripotent Stem Cell lab in Early Investigative Safety.
Linda Griffith Professor MIT Linda is Professor of Biological and Mechanical Engineering at MIT. She completed her PhD at Berkeley University and was the 2006 recipient of the MacArthur Fellowship.
Peter Hoffmann Executive Director, Preclinical Safety Novartis Peter is an MD, PhD having obtained his degrees from the Martin Luther University in Halle, Germany After an academic career he worked for Sanofi before joining Novartis ten years ago.
Mike Shuler Professor Cornell University Mike is Professor of Chemical Engineering in the School of Chemical and Biomolecular Engineering at Cornell and is currently the director for the NCI funded Center for the Microenvironment and Metastasis.
Yvonne Will Associate Research Fellow Pfizer Yvonne pursued her PhD at Oregon State University and in 2007 transferred to Pfizer to conduct in vitro safety assessment within the drug discovery process to reduce late stage attrition.
Gary Gintant Senior Group Leader Abbott Gary is a Research Fellow in the Dept. of Integrative Pharmacology, Abbott Laboratories. He is involved in multiple drug discovery initiatives and his research interests are centered on cardiovascular pharmacology.
Hirdesh Uppal Scientist, Development Sciences Genentech Hirdesh Uppal, DVM, Ph.D., is currently a Scientist in Safety Assessment & Development Sciences at Genentech Inc. During Hirdesh's time in both biotechnology and pharmaceutical companies, he has excelled at developing scientific and strategic solutions to issues vexing the industry as well as conducting scientific research & translating the needs of the drug development into meaningful outcomes. Read more...
Menghang Xia Group Leader National Center for Advancing Translational Sciences Menghang is a group leader of cellular toxicity at NCATS and also has good experience of industry having validated several targets for drug development as a senior scientist at Merck Research Lab.
Brandon Jeffy Principal Scientist, Exploratory Toxicology Celgene Brandon is a Principal Scientist in the Exploratory Toxicology department at Celgene and has a huge amount of experience in the field having worked at AstraZeneca, CeeTox and Pfizer.
Mark Labarge Staff Scientist Lawrence Berkeley National Laboratory Mark completed his PhD at Stanford University and his lab now works to understand the role of microenvironment in mammary stem cell fate decisions in the context of breast cancer.
Karen Leach Associate Research Fellow Pfizer Karen received her Ph.D in the department of Pharmacology at the University of Michigan, and currently works at Pfizer in the Compound Safety Prediction group in Medicinal Chemistry.
Andre Levchenko Professor Johns Hopkins University Andre obtained his PhD from Columbia University while simultaneously working at the Memorial Sloan-Kettering Cancer Center. Andre is now Professor of Biomedical Engineering at Johns Hopkins University.
Mayasari Lim Associate Professor Nanyang Technological University Mayasari completed her PhD at the Imperial College London in chemical engineering before shifting her focus to the development and understanding of 3D in vitro models.
Adrian Roth Section Head, Mechanistic Safety, Non- Clinical Safety Roche Adrian is heading the Mechanistic Safety Section within Roche’s Non-Clinical Safety Organisation. Prior to Roche, Adrian was a postdoctoral fellow at the University of Basel in Urs Meyer’s group.
Ranga Sarangarajan Senior VP and CSO Berg Pharma Ranga received his PhD from the University of Cincinnati before spending 15 years in academia. At Berg Pharma, he oversees an innovative research program based on discovering and validating new therapeutics.
Joe Senn Lead - Issue Management, Drug Safety Evaluation Millennium Joe is the lead of investigative toxicology and issue management in the Drug Safety Evaluation Department Millennium having previously held positions at Biogen IDEC, Boehringer Ingelheim and BMS.
Joyce Wong Associate Professor Boston University Joyce is Associate Professor at Boston University where she runs a lab that aims to understand how bioscaffold properties affect vascular smooth muscle cell migration and growth.
Arnaud Lacoste Project Team Leader, Stem Cells and Regenerative Medicine Novartis
Josef Scheiber Founder Biovariance Josef received his doctoral training at the Department of Pharmacy at the Julius-Maximilians-Universität. He then postdoc’ed at Novartis in Cambridge, Massachussetts in Lead Discovery Informatics working on methods for in silico elucidation of adverse drug reactions. Read more...